Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of agreement, Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Astellas will be responsible for conducting preclinical, clinical and commercialization activities, of gene therapy candidates using the novel capsids.
Lead Product(s): AAV Capsids
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,618.0 million Upfront Cash: $18.0 million
Deal Type: Collaboration December 02, 2021
Details:
Funds from this financing will directly fund expansion of the company’s CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors.
Lead Product(s): AAV based-gene therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Andreessen Horowitz
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 06, 2021
Details:
Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.
Lead Product(s): AAV vectors based gene therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,800.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 14, 2020
Details:
The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.
Lead Product(s): Synthetic AAV capsids Proteins
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020